The article discusses the potential impact of AI on the job market, synthesizing expert opinions and research without presenting new data or a concrete development.
Seegene's direct entry into France, Europe's second-largest molecular diagnostics market, bypasses intermediaries for stronger customer relationships and quicker market feedback. This move accelerates the adoption of its high-margin automated systems, CURECA™ and STAgora™, positioning Seegene to capture a greater share of the European market and bolster its global sales, of which Europe already constitutes 63%.
The French base will facilitate the European launch of the new fully automated CURECA™ and STAgora™ platforms.
Seegene establishes its eighth overseas subsidiary in France, its third in Europe.
Seegene establishes its eighth overseas subsidiary in France, its third in Europe.
The move targets Europe's second-largest molecular diagnostics market to boost direct sales and customer engagement.
The French base will facilitate the European launch of the new fully automated CURECA™ and STAgora™ platforms.
Seegene has established a new subsidiary in France to directly penetrate Europe's second-largest molecular diagnostics market. This expansion aims to boost direct sales of its automated platforms and strengthen its significant European revenue base.
Sign in to save notes on signals.
Sign In